ストックスクリーナーアプリを入手
272.67
1.94%
5.20
アフターアワーズ：
273.97
1.30
+0.48%
前日終値:
$267.47
開ける：
$267.55
24時間の取引高:
1.33M
Relative Volume:
1.06
時価総額：
$36.40B
収益：
$4.29B
当期純損益:
$577.22M
株価収益率:
64.79
EPS:
4.2086
ネットキャッシュフロー:
$641.34M
1週間 パフォーマンス:
-5.34%
1か月 パフォーマンス:
-1.95%
6か月 パフォーマンス:
-23.31%
1年 パフォーマンス:
-14.93%
1日の値動き範囲:
$266.27
$275.25
1週間の範囲:
$266.27
$286.75
52週間の値動き範囲:
$266.27
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Stock And 2 US Health Care Names With Earnings In Focus - simplywall.st
Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses - simplywall.st
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com - Investing.com South Africa
Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings - Quiver Quantitative
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD - Investing.com
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200 - GlobeNewswire Inc.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), Alnylam Pharma (ALNY) and Elevance Health (ELV) - The Globe and Mail
Alnylam Pharmaceuticals (ALNY) Proxy filing Summary - Quartr
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth - ChartMill
Liquidity Mapping Around (ALNY) Price Events - Stock Traders Daily
Alnylam schedules conference call on second-quarter 2026 results - Bitget
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - BioSpace
Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak - Trefis
Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - Moomoo
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY) - Seeking Alpha
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - The National Law Review
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease - BioSpace
ALNY Maintained by B of A Securities -- Price Target Lowered to $410 - GuruFocus
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Yahoo Finance
BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating - Moomoo
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says - Moomoo
Stifel reiterates Buy rating on Alnylam stock amid trial debate By Investing.com - Investing.com Canada
BofA cuts Alnylam stock price target on conservative outlook By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock - ChartMill
Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co. - Moomoo
ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410 - GuruFocus
ALNY Maintained by HC Wainwright & Co. -- Price Target Raised to $485 - GuruFocus
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions - MarketBeat
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $485 - Moomoo
Truist cuts Alnylam stock price target to $410 on ATTR outlook - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Strong Buy Opportunity with 47% Upside Potential - DirectorsTalk Interviews
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships - Sahm
Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure - Sahm
Truist Financial Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating - Moomoo
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/Ionis - MSN
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations? - Yahoo Finance
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up - 24/7 Wall St.
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)? - Yahoo Finance
3 Healthcare Stocks Investors Are Turning To As Growth Valuations Look Stretched - Sahm
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails - Yahoo Finance
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $400 to $468 - Moomoo
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns - Yahoo Finance
Alnylam Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $446.43, Implies 38% Upside - TradingView
BridgeBio hits 52-week high on late-stage trial setback for Astra/ Ionis (update) - Seeking Alpha
Alnylam, BridgeBio Gain From AstraZeneca-Ionis Drug Missing Target -- Market Talk - Moomoo
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction - Barron's
Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating - Moomoo
Stifel maintains Alnylam Pharmaceuticals (ALNY) buy recommendation - MSN
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
3.10%
大文字化:
|
ボリューム (24 時間):